Publication:
New treatment options in dry type age-related macular degeneration [Kuru tip yasa bagli maküla dejenerasyonunda yeni tedavi seçenekleri]

dc.contributor.authorsGülkas S., Çekiç O.
dc.date.accessioned2022-03-28T15:06:55Z
dc.date.accessioned2026-01-11T17:17:27Z
dc.date.available2022-03-28T15:06:55Z
dc.date.issued2016
dc.description.abstractAge-related macular degeneration (AMD) is the most common cause of visual loss in older populations in developed countries. In the pathogenesis of AMD, there are wide spectrum in which photoreceptors, retinal pigment epithelium and choroidal sheet take part. Many different factors including genetic factors as well as environmental factors are accused for the etiology. Confirming the importance of oxidative stress, complement pathway, end-toxin products of visual cycle in the pathogenesis of dry type AMD has led to development of novel therapeutic agents in this disease. This article reviews recently developed molecules that are subjected to experimental and clinical trials for the treatment of dry type AMD in addition to ongoing treatment modalities. © 2016 Gazi Eye Foundation. All Rights Reserved.
dc.identifier.issn13001256
dc.identifier.urihttps://hdl.handle.net/11424/257176
dc.language.isotur
dc.publisherGazi Eye Foundation
dc.relation.ispartofRetina-Vitreus
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectDrugs
dc.subjectDry type age-related macular degeneration
dc.subjectGeographic atrophy
dc.subjectNew treatment
dc.titleNew treatment options in dry type age-related macular degeneration [Kuru tip yasa bagli maküla dejenerasyonunda yeni tedavi seçenekleri]
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage261
oaire.citation.issue3
oaire.citation.startPage257
oaire.citation.titleRetina-Vitreus
oaire.citation.volume24

Files